Saneron CCEL Therapeutics, Inc.

Grants will fund the study of cell therapy research for the treatment of heart attacks

Published in Managed Care Law Weekly, November 6th, 2005

Cryo-Cell International, Inc., (CCEL) announced that its affiliate, Saneron CCEL Therapeutics, Inc., has been awarded two grants to study the effects of cord blood stem cells for the treatment of myocardial infarction, commonly known as heart attack.

Saneron CCEL will conduct the studies in collaboration with the University of South Florida (USF).

Saneron CCEL was awarded a STTR phase I grant by the National Institutes of Health (NIH) in the amount of $184,249 to conduct the study. In addition, the Florida High Tech Corridor External Matching Grant provided $71,736 under their SBIR/STTR Fast-Track program. The study is specifically designed to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Law Weekly

Source: Managed Care Law Weekly (2005-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry